Daewoong Pharmaceutical 'Impactamin Once'

Daewoong Pharmaceutical 'Impactamin Once'

View original image

[Asia Economy Reporter Chunhee Lee] Daewoong Pharmaceutical announced on the 21st that it will launch ‘Impactamin Once,’ which contains activated vitamin B complex in a single tablet.


Impactamin Once is a renewed version of the existing ‘Impactamin Premium Once.’ Rather than focusing solely on high dosage, this renewal was carried out to meet consumer demand for effective fatigue recovery while minimizing the burden on the body.


To this end, the strengths of Impactamin Premium Once were maintained while enhancing the vitamin B complex and adding new ingredients. It contains 120 mg of benfotiamine, an activated form of vitamin B1 with excellent bioavailability, along with eight essential vitamin B types, allowing a strong fatigue recovery effect with just one tablet per day. Additionally, 50 mg each of B2 (riboflavin) and B5 (calcium pantothenate), which help with energy production, stomatitis relief, and fatigue recovery, were further fortified.


Furthermore, selenium and vitamins C and E were added to provide antioxidant effects, enabling simultaneous fatigue recovery and antioxidant benefits with one tablet. Magnesium oxide, which neutralizes stomach acid and alleviates gastrointestinal discomfort, was newly included to reduce side effects such as heartburn that may occur after taking high-dose vitamin B.



Lee Eun-jung, head of Daewoong Pharmaceutical’s Consumer Healthcare (CH) division, said, “Impactamin Once will help modern people, who consume a lot of vitamin B due to nutritional imbalance, stress, fatigue, and various medications, maintain optimal health.” She added, “Based on our accumulated know-how and technological capabilities, we will continue to expand and develop the Impactamin lineup by reflecting consumer trends and the nutritional status of modern people.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing